The Science of Senescence

The topic of longevity has fascinated explorers since long before Ponce de Leon went looking for the fountain of youth. Today's explorations involve the study of genes and metabolic pathways in organisms that for some unknown reason live longer than their peers.

The average life expectancy has been steadily increasing over the centuries, from age 25 in prehistoric times, when the major killers were probably saber tooth tigers; to 40 at the end of the nineteenth century, when infectious diseases like diphtheria, tuberculosis and pneumonia took their toll; to 80 years today. Such an improving trend leads many to believe that the average life expectancy would continue to increase, if only we could eradicate the major killers of the industrialized world in the 21st century—cardiovascular disease, cancer and stroke. We know that it is humanly possible to live to age 122; Frenchwoman Jeanne Calment died at that ripe old age in 1997.

The topic of longevity has fascinated explorers since long before Ponce de Leon went looking for the fountain of youth. Today's explorations involve the study of genes and metabolic pathways...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

More from Scrip

ASCO: AstraZeneca Changes Management Of Breast Cancer Resistance With SERENA-6

 

AstraZeneca presented data from the SERENA-6 trial that experts said could represent a significant change in how HR+/HER2- breast cancer is treated.

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: a preview of major ASCO readouts; Roivant stays patient in deals; Lilly diversifies pain pipeline with SiteOne acquisition; Nucala gets US COPD nod; and women in Indian pharma.

ASCO: Rusfertide Inches Toward FDA Filing With Positive 32-Week Data

 

Takeda/Protagonist are awaiting 52-week data to confirm the results from the VERIFY trial of the drug in polycythemia vera.